How Recent Q3 Updates Are Shaping The CorMedix (CRMD) Investment Story [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
fair value estimate and a US$14 target reiterated rather than reset. Supportive views lean on what bullish analysts describe as "robust" preliminary Q3 sales and improving visibility on operating synergies, while more cautious voices point to execution risk and the gap between the fair value estimate and the target. As you read on, keep an eye on how this mix of optimism and caution shapes the evolving story around CorMedix, and consider how you can monitor future shifts in the narrative. Stay updated as the Fair Value for CorMedix shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on CorMedix. ?? Bullish Takeaways D. Boral Capital moved CorMedix to a Buy rating from Hold with a US$14 price target after preliminary Q3 results, signaling a more optimistic stance on the shares at current levels. The firm highlighted what it called "robust" preliminary Q3 sales and better visibility into near term operating syner
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge [Seeking Alpha]Seeking Alpha
- CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- A Look At CorMedix (CRMD) Valuation After 2026 Guidance Shift And Executive Changes [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 1/8/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- CRMD's page on the SEC website